Literature DB >> 8548178

Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations.

O Pérez1, P Gay, L Franqueza, R Carrón, C Valenzuela, E Delpón, J Tamargo.   

Abstract

1. The electromechanical effects of two enantiomers, S-16257-2 (S57) and S-16260-2 (R60), were studied and compared in guinea-pig isolated atria and ventricular papillary muscles. The possible stereoselectivity of the interaction on the cardiac Na+ channel was analysed by comparing the effects of the two enantiomers on the onset and recovery kinetics of the frequency-dependent Vmax block. 2. In spontaneously beating right atria, S57 and R60 (10(-8)M-10(-4M) exerted a negative chronotropic effect (pIC50 = 5.07 +/- 0.19 and 4.76 +/- 0.18, respectively) and prolonged the sinus node recovery time, this effect being more marked with S57. In electrically driven left atria, S57 decreased (P < 0.05) contractile force only at 10(-4M) and R60 at concentrations > or = 5 x 10(-5M), whereas in papillary muscles the negative inotropic effect appeared at concentrations > 10(-5M). 3. In papillary muscles driven at 1 Hz, S57 and R60 at concentrations higher than 5 x 10(-6M) produced a concentration-dependent decrease in the maximum upstroke velocity (Vmax) and amplitude of the cardiac action potential without altering the resting membrane potential or the action potential duration. S57 and R60 had no effect on the characteristics of the slow action potentials elicited by isoprenaline in ventricular muscle fibres depolarized in high K+ (27 mM) solution. 4. At 5 x 10(-5M), S57 and R60 produced a small tonic Vmax block. However, in muscles driven at rates between 0.5 and 3 Hz both enantiomers produced an exponential decline in Vmax (frequency-dependent Vmax block) which augmented at higher rates of stimulation. The onset and offset rates of the frequency-dependent Vmax block were similar for both drugs. Both S57 and R60 prolonged the recovery time constant from the frequency-dependent block from 20.1 +/- 2.9 ms to 2-3 s.5. At 5 x 10-5 M, S57 and R60 shifted the membrane responsiveness curve in a hyperpolarizing direction.6. It can be concluded that S57 and R60, the two enantiomers of the new bradycardic agent, produced a similar frequency-dependent Vmax block which indicated that the interaction with the Na+ channel was not stereospecific. The analysis of the onset and offset kinetics of the frequency-dependent Vmax block suggested that both enantiomers can be considered as Na+ channel blockers with intermediate kinetics,e.g., class IA antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8548178      PMCID: PMC1908524          DOI: 10.1111/j.1476-5381.1995.tb15002.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion.

Authors:  H Boudoulas; S E Rittgers; R P Lewis; C V Leier; A M Weissler
Journal:  Circulation       Date:  1979-07       Impact factor: 29.690

Review 2.  Oxygen consumption of the heart. Newer concepts of its multifactoral determination.

Authors:  E H Sonnenblick; J Ross; E Braunwald
Journal:  Am J Cardiol       Date:  1968-09       Impact factor: 2.778

3.  Importance of physico-chemical properties in determining the kinetics of the effects of Class I antiarrhythmic drugs on maximum rate of depolarization in guinea-pig ventricle.

Authors:  T J Campbell
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

Review 4.  Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs.

Authors:  L M Hondeghem; B G Katzung
Journal:  Annu Rev Pharmacol Toxicol       Date:  1984       Impact factor: 13.820

Review 5.  Maximal coronary flow and the concept of coronary vascular reserve.

Authors:  J I Hoffman
Journal:  Circulation       Date:  1984-08       Impact factor: 29.690

6.  Shortening of the action potential and reduction of pacemaker activity by lidocaine, quinidine, and procainamide in sheep cardiac purkinje fibers. An effect on Na or K currents?

Authors:  E Carmeliet; T Saikawa
Journal:  Circ Res       Date:  1982-02       Impact factor: 17.367

7.  Interval-dependent effects of small antiarrhythmic drugs on excitability of guinea-pig myocardium.

Authors:  K R Courtney
Journal:  J Mol Cell Cardiol       Date:  1980-11       Impact factor: 5.000

8.  Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification.

Authors:  T J Campbell
Journal:  Cardiovasc Res       Date:  1983-06       Impact factor: 10.787

9.  Validity of Vmax as a measure of the sodium current in cardiac and nervous tissues.

Authors:  L M Hondeghem
Journal:  Biophys J       Date:  1978-07       Impact factor: 4.033

10.  Electrophysiological effects of bunaphtine on isolated rat atria.

Authors:  J Tamargo
Journal:  Eur J Pharmacol       Date:  1980-03-07       Impact factor: 4.432

View more
  10 in total

1.  New evidence for coupled clock regulation of the normal automaticity of sinoatrial nodal pacemaker cells: bradycardic effects of ivabradine are linked to suppression of intracellular Ca²⁺ cycling.

Authors:  Yael Yaniv; Syevda Sirenko; Bruce D Ziman; Harold A Spurgeon; Victor A Maltsev; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2013-05-05       Impact factor: 5.000

2.  Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells.

Authors:  P Bois; J Bescond; B Renaudon; J Lenfant
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2.

Authors:  E Delpón; C Valenzuela; O Pérez; L Franqueza; P Gay; D J Snyders; J Tamargo
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels.

Authors:  Benjamin Hackl; Peter Lukacs; Janine Ebner; Krisztina Pesti; Nicholas Haechl; Mátyás C Földi; Elena Lilliu; Klaus Schicker; Helmut Kubista; Anna Stary-Weinzinger; Karlheinz Hilber; Arpad Mike; Hannes Todt; Xaver Koenig
Journal:  Front Pharmacol       Date:  2022-05-02       Impact factor: 5.988

5.  Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels.

Authors:  A Bucchi; A Tognati; R Milanesi; M Baruscotti; D DiFrancesco
Journal:  J Physiol       Date:  2006-02-16       Impact factor: 5.182

6.  Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine.

Authors:  Annalisa Bucchi; Mirko Baruscotti; Dario DiFrancesco
Journal:  J Gen Physiol       Date:  2002-07       Impact factor: 4.086

Review 7.  HCN Channels Modulators: The Need for Selectivity.

Authors:  Maria Novella Romanelli; Laura Sartiani; Alessio Masi; Guido Mannaioni; Dina Manetti; Alessandro Mugelli; Elisabetta Cerbai
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

8.  hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Authors:  Dario Melgari; Kieran E Brack; Chuan Zhang; Yihong Zhang; Aziza El Harchi; John S Mitcheson; Christopher E Dempsey; G André Ng; Jules C Hancox
Journal:  J Am Heart Assoc       Date:  2015-04-24       Impact factor: 5.501

9.  Chronotropic Modulation of the Source-Sink Relationship of Sinoatrial-Atrial Impulse Conduction and Its Significance to Initiation of AF: A One-Dimensional Model Study.

Authors:  Francesca Cacciani; Massimiliano Zaniboni
Journal:  Biomed Res Int       Date:  2015-07-01       Impact factor: 3.411

10.  The Effect of Ivabradine on the Human Atrial Myocardial Contractility in an In Vitro Study.

Authors:  Ryan Chaban; Katja Buschmann; Anna Krausgrill; Andres Beiras-Fernandez; Christian-Friedrich Vahl
Journal:  Cardiol Res Pract       Date:  2019-10-30       Impact factor: 1.866

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.